-
Alexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder
Friday, July 16, 2021 - 7:29am | 249Read More...Alexion Pharmaceuticals Inc (NASDAQ: ALXN) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met its primary endpoint, with a statistically significant change in MG-ADL score...
-
Argenx's Efgartigimod US Application In Neuromuscular Disorder Accepted For Review
Tuesday, March 2, 2021 - 6:40am | 161Read More...The FDA has accepted for review Argenx SE's (NASDAQ: ARGX) marketing application seeking approval for intravenous (IV) efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Myasthenia gravis is a neuromuscular disorder primarily characterized by muscle...
-
Ra Pharma Shares Rally: What You Need To Know
Monday, December 10, 2018 - 2:54pm | 353Read More...Ra Pharmaceuticals Inc (NASDAQ: RARX) shares are surging higher Monday morning, reacting to an announcement by the company concerning clinical trial results of its autoimmune disorder drug. What Happened Ra Pharma said topline data from the mid-stage trial of Zilucoplan in patients with...
